Bone Biologics Corporation BBLG
Nov 3, 2026, 3:02 PM EST
- YTD
- -74.70%
- 1 year
- -82.11%
- Market cap
- 1.24M
- EPS (ttm)
- -1.02
- Shares out
- 2.46M
- Forward P/E
- -0.41
- YTD return
- -74.70%
- 1-year return
- -82.11%
- Volume
- 18.77K
- Avg volume
- 379.65K
- Open
- 0.3667
- Previous close
- 0.3709
- Day's range
- 0.3667 – 0.3712
- 52-week range
- 0.361 – 2.39
- Beta
- 0.74
- Price target
- 16.75 (+4466.5%)
- Earnings date
- Aug 9, 2024
YTD -1.1732 (-76.18%)
Key statistics
- Enterprise value
- -188.37K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.83M
- Total cash
- 2.33M
- Total debt
- 0
- Return on equity
- -119.03%
- Short % of float
- 3.49%
- 50-day average
- 1.34
- 200-day average
- 1.60
Analyst view
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.65.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -2.37 | -1.77 | -295.00% |
| Aug 9, 2024 | Jun 1, 2024 | -1.39 | -0.67 | +0.72 | +51.80% |
| Aug 9, 2024 | Jun 1, 2024 | -1.39 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -7.60 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -7.60 | -1.31 | +6.29 | +82.76% |
| Apr 4, 2024 | Dec 1, 2023 | -5.56 | — | — | — |
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bonebiologics.com
News
Bone Biologics Q3 EPS $(0.17) Beats $(0.18) Estimate 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Drops By 76.4% 
Bone Biologics Expands Trial Sites 
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - 12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on BBLG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FRELICK JEFFREY | Chief Executive Officer | Purchase | Sep 10, 2023 | 17,204 |
| WALSH DEINA H | Chief Financial Officer | Purchase | Sep 12, 2023 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 1.32% | 32,851 | 29.57K | Sep 29, 2024 |
| Morgan Stanley | 1.14% | 28,527 | 25.68K | Sep 29, 2024 |
| HRT Financial LP | 0.89% | 22,276 | 20.05K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.07% | 1,786 | 1.61K | Sep 29, 2024 |
| CWM, LLC | 0.02% | 444 | 399 | Sep 29, 2024 |
| MFA Wealth Advisors, LLC | 0.02% | 403 | 362 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.36% | 8,910 | 8.02K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 3,936 | 3.54K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 2,747 | 2.47K | Oct 30, 2024 |